A. Amgen, . Bayer, . Biocartis, B. Bioinvent, . Medicines et al., SP has received education grants, provided consultation, attended advisory boards, or provided lectures for AbbVie, LC has served as consultant or advisor to Bristol-Myers Squibb and Merck Sharp and Dohme, 2017.

P. Fabre, G. , B. Squibb, M. Sharp-dohme, . Astrazeneca et al., CG has received honoraria as consultant or advisor or speaker bureau member for AstraZeneca, Bristol-Myers Squibb, F Hoffmann-La Roche, and Merck Sharp and Dohme, and has received funds (to organisation) from Merck Sharp and Dohme. MR has served as a consultant and provided lectures for Amgen, Gritstone. AMDG has served as a consultant or advisor to Incyte, 2019.

. Ministero-della-salute, , 2020.

, COVID-19): cases in the US, Centers for Disease Control and Prevention. Coronavirus disease, 2019.

A. Bernheim, X. Mei, and M. Huang, Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection, Radiology, 2020.

F. Pan, T. Ye, and P. Sun, Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia, Radiology, vol.13, 2020.

J. Remon, F. Passiglia, and M. J. Ahn, Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations, J Thorac Oncol, 2020.

M. Nishino, N. H. Ramaiya, and M. M. Awad, PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course, Clin Cancer Res, vol.22, pp.6051-60, 2016.

M. Delaunay, G. Prévot, S. Collot, L. Guilleminault, A. Didier et al., Management of pulmonary toxicity associated with immune checkpoint inhibitors, Eur Respir Rev, vol.28, 2019.

J. C. Soria, Y. Ohe, and J. Vansteenkiste, Osimertinib in untreated EGFRmutated advanced non-small cell lung cancer, N Engl J Med, vol.378, pp.113-138, 2018.

D. E. Magee, A. E. Hird, and Z. Klaassen, Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials, Ann Oncol, vol.31, pp.50-60, 2020.

G. Lehne and K. Lote, Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review, Acta Oncol, vol.29, pp.113-137, 1990.

W. Liang, W. Guan, and R. Chen, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol, vol.21, pp.335-372, 2020.

, US Food & Drug Administration. Emergency use authorizations: in vitro diagnostics EUAs, 2020.